Gilead Sciences ( GILD -1.7% ) unit Kite Pharma will collaborate with Humanigen ( OTCQB:HGEN +8.7% ) on a Phase 1/2 clinical trial evaluating the combination of CAR T therapy Yescarta (axicabtagene ciloleucel) and lenzilumab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Jan 1, 2019 | seekingalpha.comFinally, another of Fish’s cases, Juno Therapeutics v. Kite Pharma, was also named an “Impact Case of the Year,” an honor the firm shared with co-counsel Orrick Herrington & Sutcliffe.
Sep 8, 2022 | fr.com“Kite Pharma purchased 20 acres for a state-of-the-art manufacturing facility.
Sep 13, 2022 | naiopmd.orgKite was acquired by Gilead Sciences, Inc. later in 2017 after the Daiichi Sankyo partnership agreement.
Dec 7, 2022 | pharmajournalist.comGilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients.
Dec 12, 2022 | pharmaceutical-technology.comGilead Sciences subsidiary Kite Pharma has entered into a purchase deal with Tmunity Therapeutics — the company founded by CAR-T cell pioneer Carl June — gaining access to Tmunity’s “armored” CAR-T cell platform.
Dec 21, 2022 | fdanews.comKite’s acquisition of Tmunity, founded by Carl June, creates a strong bridge between the BioHealth Capital Region, where Kite maintains its manufacturing capabilities in Frederick, and the Greater Philadelphia biohub.
Dec 19, 2022 | biobuzz.io